Advertisement

Menopausal Symptoms

  • Debra L. Barton Email author
  • Aditya Bardia
  • Charles Loprinzi
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Menopause is considered to be a major turning point in a women's life. It is accompanied by a variety of physical and psychological changes that can significantly impair one's quality of life. Menopausal symptoms among cancer survivors often occur at an earlier age, and can be more frequent, last longer, and be more severe than are seen in women experiencing natural menopause. A recent NIH state of the science report listed four symptoms as strongly associated with menopause: hot flashes with/without night sweats, osteoporosis, vaginal dryness, and insomnia. Other symptoms variably associated with menopause include urinary incontinence, mood swings, irritability, and cognitive impairment.

Traditionally, hormone replacement therapy (HRT) (estrogen and progesterone) has been the mainstay of therapy for menopausal symptoms. However, recent trials have raised concerns about risks of breast cancer, thrombosis, stroke, and cardiovascular mortality. Various novel nonhormonal therapeutic options have emerged for the management of menopausal symptoms. Newer antidepressants appear to be efficacious in reducing hot flashes. Bisphosphonates, along with calcium and vitamin D, remain the front line therapy for prevention and treatment of osteoporosis, but long-term efficacy has not been established. Vaginal dryness responds well to local estrogens and vaginal lubricants. There is evidence that new nonbenzodiazepines have efficacy in treating insomnia. However, despite progress in effective nonhormonal therapies, menopausal symptoms remain a major cause of morbidity among cancer survivors and compassionate management of individual symptoms is crucial.

Key Words:

Menopause Cancer survivors Hot flash Osteoporosis Vaginal dryness Insomnia 

References

  1. 1.
    National Institutes of Health. 2005; National Institutes of Health State-of-the-Science Conference statement: Management of menopause-related symptoms. Ann Intern Med 142:(12 Pt 1)1003–13Google Scholar
  2. 2.
    Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. 2000; Tamoxifen-induced hot flashes. Clin Breast Cancer 1:(1)52–6PubMedGoogle Scholar
  3. 3.
    Boekhout AH, Beijnen JH, Schellens JH. 2006; Symptoms and treatment in cancer therapy-induced early menopause. Oncologist 11:(6)641–54PubMedGoogle Scholar
  4. 4.
    Carpenter J, Andrykowski M: 1999; Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 26:(8)1311–17PubMedGoogle Scholar
  5. 5.
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. 1999; Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17:2365–70PubMedGoogle Scholar
  6. 6.
    Gallicchio L, Whiteman M, Tomic D, Miller K, Langenberg P, Flaws J. 2006; Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 85:(5)1432–40PubMedGoogle Scholar
  7. 7.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. 2002; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288:(3)321–33Google Scholar
  8. 8.
    Schow DA, Renfer LG, Rozanski TA, Thompson IM. 1998; Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 91:(9)855–7PubMedGoogle Scholar
  9. 9.
    Carpenter J, Adrykowski M, Cordova M,. et al. 1998; Hot flashes in postmenopausal women treated for breast carcinoma. Cancer 82:1682–91PubMedGoogle Scholar
  10. 10.
    Finck G, Barton DL, Loprinzi CL,. et al. 1998; Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 16:(5)327–33PubMedGoogle Scholar
  11. 11.
    Greendale GA, Reboussin BA, Hogan P,. et al. 1998; Symptom relief and side effects of postmenopausal hormones: Results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 92:982–8PubMedGoogle Scholar
  12. 12.
    Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. 2002; Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 77:(11)1207–18. ReviewPubMedGoogle Scholar
  13. 13.
    Berendsen HH. 2000; The role of serotonin in hot flushes. Maturitas 36:(3)155–64. ReviewPubMedGoogle Scholar
  14. 14.
    Dalal S, Zhukovsky DS. 2006; Pathophysiology and management of hot flashes. J Support Oncol 4:(7)315–20, 325PubMedGoogle Scholar
  15. 15.
    Loprinzi CL, Michalak JC, Quella SK,. et al. 1994; Megesterol acetate for the prevention of hot flashes. N Engl J Med 331:347–52PubMedGoogle Scholar
  16. 16.
    Nand SL, Webster MA, Baber R,. et al. 1998; Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Climacteric 1:211–8PubMedGoogle Scholar
  17. 17.
    Lacey JV Jr, Mink PJ, Lubin JH,. et al. 2002; Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc 288:334–41Google Scholar
  18. 18.
    Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. 1995; The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:(24)1589–93PubMedGoogle Scholar
  19. 19.
    Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD,. et al. 1991; A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc 265:1985–90Google Scholar
  20. 20.
    Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, Venturini S, Porcile G, Pronzato P, Costantini M, Rosso R. 2002; Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: A randomized study. Ann Oncol 13:(6)883–8PubMedGoogle Scholar
  21. 21.
    Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden D 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW. 2006; Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 24:(9)1409–14. Epub 2006 Feb 27PubMedGoogle Scholar
  22. 22.
    Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, Pierce HI, Dragalin V, Morrow GR. 2000; Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 132:(10)788–93PubMedGoogle Scholar
  23. 23.
    Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, Hayes DF, Isaacs C. 2005; Paroxetine is an effective treatment for hot flashes: Results from a prospective randomized clinical trial. J Clin Oncol 23:(28)6919–30PubMedGoogle Scholar
  24. 24.
    Stearns V, Beebe KL, Iyengar M, Dube E. 2003; Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. J Am Med Assoc 289:(21)2827–34Google Scholar
  25. 25.
    Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ. 2000; Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 356:(9247)2059–63PubMedGoogle Scholar
  26. 26.
    Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. 2002; Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20:(6)1578–83PubMedGoogle Scholar
  27. 27.
    Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. 2006; Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 12:(2)114–22PubMedGoogle Scholar
  28. 28.
    Gordon PR, Kerwin JP, Boesen KG, Senf J. 2006; Sertraline to treat hot flashes: A randomized controlled, double-blind, crossover trial in a general population. Menopause 13:(4)568–75PubMedGoogle Scholar
  29. 29.
    Loprinzi CL, Flynn PJ, Carpenter LA, Atherton P, Barton DL, Shanafelt TD, Rummans TA, Sloan JA, Adjei AA, Mincey BA, Fitch TR, Collins M 2005; Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med 8:(5)924–30PubMedGoogle Scholar
  30. 30.
    Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E, Haiva-Mallinen L, Tapanainen JS. 2005; Citalopram and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 12:(1)18–26PubMedGoogle Scholar
  31. 31.
    Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. 2005; Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:(36)9312–8PubMedGoogle Scholar
  32. 32.
    Borges S, Desta Z, Li L, Skaar T, Ward B, Nguyen A, Jin Y,. et al. 2006; Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61–74PubMedGoogle Scholar
  33. 33.
    Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ. 2005; Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial. Lancet 366:(9488)818–24PubMedGoogle Scholar
  34. 34.
    Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. 2003; Gabapentin's effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 101:(2)337–45PubMedGoogle Scholar
  35. 35.
    Reddy SY, Warner H, Guttuso T Jr, Messing S, DiGrazio W, Thornburg L, Guzick DS. 2006; Gabapentin, estrogen, and placebo for treating hot flushes: A randomized controlled trial. Obstet Gynecol 108:(1)41–8PubMedGoogle Scholar
  36. 36.
    Loprinzi CL, Kugler RW, Barton DL,. et al. 2007; A phase III randomized trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone. J Clin Oncol 25:308–12PubMedGoogle Scholar
  37. 37.
    Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P. 1998; Prospective evaluation of vitamin E for hot flashes in breast cancer survivors J Clin Oncol 16:(2)495–500PubMedGoogle Scholar
  38. 38.
    Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. 2006; Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. J Am Med Assoc 295:(17)2057–71. ReviewGoogle Scholar
  39. 39.
    Vincent A, Barton DL, Mandrekar JN, Cha SS, Zais T, Wahner-Roedler DL, Keppler MA, Kreitzer MJ, Loprinzi C. Acupuncture for hot flashes: A randomized, sham-controlled clinical study. Menopause 2006; [Epub ahead of print]Google Scholar
  40. 40.
    Liu J, Burdette J, Xu H, Gu C, Breemen R, van Bhat K,. et al. 2001; Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 49:2472–79PubMedGoogle Scholar
  41. 41.
    Shanafelt TD, Loprinzi CL. 2003Improving quality of life for women at high risk for breast cancer: Symptom management without estrogen. In: Morrow M, Jordan VC (eds), Managing Breast Cancer Risk. BC Decker, Inc., Hamilton, Ontario, pp. 227–38,Google Scholar
  42. 42.
    Mauck KF, Clarke BL. 2006; Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc 81:(5)662–72. ReviewPubMedGoogle Scholar
  43. 43.
    Lester J, Dodwell D, McCloskey E, Coleman R. 2005; The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31:115–42PubMedGoogle Scholar
  44. 44.
    Shapiro C, Maola J, Leboff M. 2001; Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early stage breast cancer. J Clin Oncol 19:3306–11PubMedGoogle Scholar
  45. 45.
    Looker AC, Orwoll ES, Johnston CC . Jr, et al. 1997; Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12:1761–8PubMedGoogle Scholar
  46. 46.
    Anderson GL, Limacher M, Assaf AR,. et al. 2004; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. J Am Med Assoc 291:1701–12Google Scholar
  47. 47.
    Cauley JA, Robbins J, Chen Z,. et al. 2003Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized controlled trial. J Am Med Assoc; 290:1729–38Google Scholar
  48. 48.
    Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002; Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 23:(4)517–23. ReviewPubMedGoogle Scholar
  49. 49.
    Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002; Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:(4)508–16. ReviewPubMedGoogle Scholar
  50. 50.
    Chesnut CH, Skag A, Christiansen C,. et al. 2004; Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res 19:1241–9Google Scholar
  51. 51.
    Nguyen ND, Eisman JA, Nguyen TV. 2006; Anti-hip fracture efficacy of biophosphonates: A Bayesian analysis of clinical trials. J Bone Miner Res 21:(2)340–9PubMedGoogle Scholar
  52. 52.
    Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC 2nd, Hirsch LJ, Oppenheimer L, Thompson D. 1997; Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. J Am Med Assoc 277:(14)1159–64Google Scholar
  53. 53.
    Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, Suarez-Almazor ME. 1999; A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 26:(5)1148–57PubMedGoogle Scholar
  54. 54.
    Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor M. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000; (2):CD001347. ReviewGoogle Scholar
  55. 55.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL, (2004); Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg 62:527–34Google Scholar
  56. 56.
    Migliorati CA, Siegel MA, Elting LS. 2006; Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 7:(6)508–14. ReviewPubMedGoogle Scholar
  57. 57.
    Marx RE. 2003; Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61:(9)1115–7PubMedGoogle Scholar
  58. 58.
    Marx RE, Sawatari Y, Fortin M, Broumand V. 2005; Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:(11)1567–75PubMedGoogle Scholar
  59. 59.
    Durie BG, Katz M, Crowley J. 2005; Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 353:(1)99–102; discussion 99–102PubMedGoogle Scholar
  60. 60.
    Woo SB, Hellstein JW, Kalmar JR. 2006; Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:(10)753–61. ReviewPubMedGoogle Scholar
  61. 61.
    Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A,. et al. 2006; Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24:945–52PubMedGoogle Scholar
  62. 62.
    Ettinger B, Black DM, Mitlak BH . et al. 1999; Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial, J Am Med Assoc 282:637–45Google Scholar
  63. 63.
    Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. 2002; Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162:(10)1140–3PubMedGoogle Scholar
  64. 64.
    Kanis JA, Johnell O, Black DM, Downs RW Jr, Sarkar S, Fuerst T, Secrest RJ, Pavo I. 2003; Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33:(3)293–300PubMedGoogle Scholar
  65. 65.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR. Continuing Outcomes Relevant to Evista (CORE) Investigators. 2005; Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:(9)1514–24PubMedGoogle Scholar
  66. 66.
    Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. 2000; A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:(4)267–76PubMedGoogle Scholar
  67. 67.
    Neer RM, Arnaud CD, Zanchetta JR,. et al. 2001; Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–41PubMedGoogle Scholar
  68. 68.
    Southby J, Kissin MW, Danks JA . et al. 1990; Immunohistochemical localisation of parathyroid hormone-related protein in human breast cancer, Cancer Res 50:7710–6PubMedGoogle Scholar
  69. 69.
    Gold DT, Pantos BS, Masica DN, Misurski DA, Marcus R. 2006; Initial experience with teriparatide in the United States. Curr Med Res Opin 22:(4)703–8PubMedGoogle Scholar
  70. 70.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. 2004; The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:(5)459–68PubMedGoogle Scholar
  71. 71.
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. 2005; Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:(5)2816–22PubMedGoogle Scholar
  72. 72.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. AMG 162 Bone Loss Study Group. 2006; Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:(8)821–31PubMedGoogle Scholar
  73. 73.
    Sambrook P, Cooper C. 2006; Osteoporosis. Lancet 367:(9527)2010–8. ReviewPubMedGoogle Scholar
  74. 74.
    Schoofs MW, Klift M, van der Hofman A, de Laet CE, Herings RM, Stijnen T, Pols HA, Stricker BH. 2003; Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139:(6)476–82PubMedGoogle Scholar
  75. 75.
    LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, Cornoni-Huntley J, Ostfeld AM. 1990; Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 322:(5)286–90PubMedGoogle Scholar
  76. 76.
    Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, Klift M, van der Pols HA. 2004; Use of statins and fracture: Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:(2)146–52PubMedGoogle Scholar
  77. 77.
    Taaffe DR, Duret C, Wheeler S, Marcus R. 1999; Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults. J Am Geriatr Soc 47:1208–14PubMedGoogle Scholar
  78. 78.
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. 2001; Osteoporosis prevention, diagnosis, and therapy. J Am Med Assoc 285:(6)785–95. ReviewGoogle Scholar
  79. 79.
    Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. 2005; Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. J Am Med Assoc 293:2257–64Google Scholar
  80. 80.
    Baulieu E, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B,. et al. 2000; Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 97:4279–84PubMedGoogle Scholar
  81. 81.
    Labrie F, Diamond P, Cusan L, Gomez J, Belanger A, Candas B. 1997; Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women J Clin Endocrinol Metab 82:3498–505PubMedGoogle Scholar
  82. 82.
    Hartkamp A, Geenen R, Godaert G, Bijl M, Bijlsma J, Derksen R. 2004; The effect of dehydroepiandosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum 50:3591–5PubMedGoogle Scholar
  83. 83.
    Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. 2000; A prospective population-based study of menopausal symptoms, Obstet Gynecol 96:351–8PubMedGoogle Scholar
  84. 84.
    Kalogeraki A, Tamiolakis D. 1996; Cigarette smoking and vaginal atrophy in postmenopausal women. In Vivo 10:(6)597–600PubMedGoogle Scholar
  85. 85.
    Smith P. 1993; Estrogens and the urogenital tract: Studies on steroid hormone receptors and a clinical study on a new oestradiol-releasing vaginal ring, Acta Obstet Gynecol Scand Suppl 157:1–26PubMedGoogle Scholar
  86. 86.
    Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, Klein KO. 2002; Treatment of urogenital atrophy with low-dose estradiol: Preliminary results. Menopause 9:(3)179–87PubMedGoogle Scholar
  87. 87.
    Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 2000; 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7:(3)156–61PubMedGoogle Scholar
  88. 88.
    Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, Fraser ID. 1996; A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 103:(4)351–8PubMedGoogle Scholar
  89. 89.
    Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; (4):CD001500. ReviewGoogle Scholar
  90. 90.
    Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. 2001; The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: A comparative study. J Obstet Gynaecol Res 27:(5)255–60PubMedGoogle Scholar
  91. 91.
    Naessen T, Rodriguez-Macias K, Lithell H. 2001; Serum lipid profile improved by ultra-low doses of 17 B-estradiol in elderly women. J Clin Endocrinol Metab 86:2757–62PubMedGoogle Scholar
  92. 92.
    Loprinzi CL, Abu-Ghazaleh S, Sloan JA, Haelst-Pisani C, vanHammer AM, Rowland KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. 1997; Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 15:(3)969–73PubMedGoogle Scholar
  93. 93.
    Bygdeman M, Swahn ML. 1996; Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23:(3)259–63PubMedGoogle Scholar
  94. 94.
    Caswell M, Kane M. 2002; Comparison of the moisturization efficacy of two vaginal moisturizers: Pectin versus polycarbophil technologies. J Cosmet Sci 53:(2)81–7PubMedGoogle Scholar
  95. 95.
    Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marre GB. 2006; Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimittelforschung 56:(3)230–8PubMedGoogle Scholar
  96. 96.
    Rosenthal MB. 2003; Epidemiology, sleep, and menopause. Menopause 10:4–5PubMedGoogle Scholar
  97. 97.
    Kalleinen N, Polo O, Himanen SL, Joutsen A, Urrila AS, Polo-Kantola P. 2006; Sleep deprivation and hormone therapy in postmenopausal women. Sleep Med 7;(5)436–47PubMedGoogle Scholar
  98. 98.
    Krystal AD. 2003Insomnia in women. Clin Cornerstone.; 5:(3)41–50PubMedGoogle Scholar
  99. 99.
    Kravitz HM, Ganz PA, Brombergerj,. et al. 2003; Sleep difficulty in women at midlife: A community survey of sleep and the menopausal transition. Menopause 10:19–28PubMedGoogle Scholar
  100. 100.
    Young T, Finn L, Austin D, Peterson A. 2003; Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 167:(9)1181–5. Epub 2003 Feb 13PubMedGoogle Scholar
  101. 101.
    Roth T, Ancoli-Israel S. 1999; Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. II. Sleep 22:(Suppl 2)S354–8PubMedGoogle Scholar
  102. 102.
    Katz DA, McHorney CA. 2002; The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 51:(3)229–35PubMedGoogle Scholar
  103. 103.
    Benca RM. 2001; Consequences of insomnia and its therapies. J Clin Psychiatry 62:(Suppl 10)33–8. ReviewPubMedGoogle Scholar
  104. 104.
    Krystal AD, Edinger J, Wohlgemuth. 1998; Sleep in peri-menopausal and postmenopausal. Sleep Med Rev 2:243–53PubMedGoogle Scholar
  105. 105.
    Brugge KL, Kripke DE, Ancoli-Israel S, Gaffinkel L. 1989; The association of menopausal status and age with sleep disorders. Sleep Res 18:208Google Scholar
  106. 106.
    Ohayon MM. 2006; Severe hot flashes are associated with chronic insomnia. Arch Intern Med 166:(12)1262–8PubMedGoogle Scholar
  107. 107.
    McEwen BS, Alves SE. 1999; Estrogen action in the central nervous system. Endocrinol Rev 20:279–307Google Scholar
  108. 108.
    Gorfine T, Assaf Y, Goshen-Gottstein Y, Yeshurun Y, Zisapel N. 2006; Sleep-anticipating effects of melatonin in the human brain. Neuroimage 31:410–8PubMedGoogle Scholar
  109. 109.
    Shaver J, Zenk S. 2000; Sleep disturbance in menopause. J Womens Health Gend Based Med. 9:109–18PubMedGoogle Scholar
  110. 110.
    Krystal AD, Edinger J, Wohlgemuth W, Marsh GR. 1998; Sleep in peri-menopausal and postmenopausal women. Sleep Med Rev 2:(4)243–53PubMedGoogle Scholar
  111. 111.
    Becker P. 2005; Pharmacologic and nonpharmacologic treatments for insomnia. Neurol Clin 23:1149–63PubMedGoogle Scholar
  112. 112.
    Edinger JD, Wohlgemuth WK, Radtke RA,. et al. 2001; Cognitive behavioral therapy for treatment of chronic primary insomnia: A randomized controlled trial. J Am Med Assoc 285:1856–64Google Scholar
  113. 113.
    Kamel NS, Gammack JK. 2006; Insomnia in the elderly: Cause, approach, and treatment. Am J Med 119:(6)463–9. ReviewPubMedGoogle Scholar
  114. 114.
    Holm KJ, Goa KL. 2000; Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:(4)865–89. ReviewPubMedGoogle Scholar
  115. 115.
    Dooley M, Plosker GL. 2000; Zaleplon: A review of its use in the treatment of insomnia. Drugs 60:(2)413–45. ReviewPubMedGoogle Scholar
  116. 116.
    Ancoli-Israel S, Ayalon L. 2006; Diagnosis and treatment of sleep disorders in older adults. Am J Geriatr Psychiatry 14:(2)95–103. ReviewPubMedGoogle Scholar
  117. 117.
    Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, Mangano R. 2000; Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 20:(3)328–37PubMedGoogle Scholar
  118. 118.
    Najib J. 2006; Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 28:(4)491–516. ReviewPubMedGoogle Scholar
  119. 119.
    Melton ST, Wood JM, Kirkwood CK. 2005; Eszopiclone for insomnia. Ann Pharmacother 39:(10)1659–66. Epub 2005 Aug 30. ReviewPubMedGoogle Scholar
  120. 120.
    Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. 2003; Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26:(7)793–9PubMedGoogle Scholar
  121. 121.
    Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, Foster AC. 2006; Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J Pharmacol Exp Ther 317:(1)369–77PubMedGoogle Scholar
  122. 122.
    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. 2006; Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7:(4)312–8PubMedGoogle Scholar
  123. 123.
    Roth T, Stubbs C, Walsh JK. 2005; Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28:(3)303–7PubMedGoogle Scholar
  124. 124.
    Erman M, Seiden D, Zammit G, Sainati S, Zhang J. 2006; An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 7:(1)17–24. Epub 2005 Nov 23PubMedGoogle Scholar
  125. 125.
    Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. 2000; Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33:(2)47–53PubMedGoogle Scholar
  126. 126.
    Andrade C, Srihari BS, Reddy KP, Chandramma L. 2001; Melatonin in medically ill patients with insomnia: A double-blind, placebo-controlled study. J Clin Psychiatry 62:(1)41–5PubMedGoogle Scholar
  127. 127.
    Hallam KT, Olver JS, McGrath C, Norman TR. 2003; Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. Hum Psychopharmacol 18:(8)619–25PubMedGoogle Scholar
  128. 128.
    Morin CM, Culbert JP, Schwartz SM. 1994; Nonpharmacological interventions for insomnia: A meta-analysis of treatment efficacy. Am J Psychiatry 151:1172–80PubMedGoogle Scholar
  129. 129.
    Sack RL, Brandes RW, Kendall AR, Lewy AJ. 2000; Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 343:(15)1070–7PubMedGoogle Scholar
  130. 130.
    Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. 2002; Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia – a randomized, double-blind, comparative clinical study. Eur J Med Res 7:(11)480–6PubMedGoogle Scholar
  131. 131.
    Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. 2005; Valerian-hops combination and diphenhydramine for treating insomnia: A randomized placebo-controlled clinical trial. Sleep 28:(11)1465–71PubMedGoogle Scholar
  132. 132.
    Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-Reich A. 2004; Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer 100:(10)2253–60PubMedGoogle Scholar
  133. 133.
    Khalsa SB. 2004; Treatment of chronic insomnia with yoga: A preliminary study with sleep-wake diaries. Appl Psychophysiol Biofeedback 29:(4)269–78PubMedGoogle Scholar
  134. 134.
    Manjunath NK, Telles S. 2005; Influence of Yoga and Ayurveda on self-rated sleep in a geriatric population. Indian J Med Res 121:(5)683–90PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Debra L. Barton
    • 1
    Email author
  • Aditya Bardia
  • Charles Loprinzi
  1. 1.Department of Medical OncologyMayo Clinic Cancer CenterRochesterUSA

Personalised recommendations